AFC-HD AMS Life Science Co

AFC-HD AMS Life Science Co Current Liabilities

The Current Liabilities of AFC-HD AMS Life Science Co (2927.T) as of Nov 4, 2026 is 24.15 B JPY. In the previous year, Current Liabilities was 33.75 B JPY — a change of -28.43% (lower).

Current Liabilities

24.15 BJPY

YoY

-28.43%

Last updated:

Current Liabilities of AFC-HD AMS Life Science Co is 2026 24.15 B JPY. Current Liabilities of AFC-HD AMS Life Science Co was 2025 33.75 B JPY. It decreases by -28.43% lower compared to the previous year.

The AFC-HD AMS Life Science Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
7.65 B JPY
Jan 1, 2020
6.28 B JPY
Jan 1, 2021
12.38 B JPY
Jan 1, 2022
12.28 B JPY
Jan 1, 2023
13.43 B JPY
Jan 1, 2024
16.20 B JPY
Jan 1, 2025
33.75 B JPY
Jan 1, 2026
24.15 B JPY
The AFC-HD AMS Life Science Co Current Liabilities history
YEARCurrent LiabilitiesYoY
24.15 BJPY-28.43%
33.75 BJPY+108.39%
16.20 BJPY+20.55%
13.43 BJPY+9.44%
12.28 BJPY-0.84%
12.38 BJPY+97.08%
6.28 BJPY-17.91%
7.65 BJPY+16.49%
6.57 BJPY-31.62%
9.61 BJPY+42.88%
6.72 BJPY-12.83%
7.71 BJPY+1.43%
7.61 BJPY+1.29%
7.51 BJPY-12.53%
8.58 BJPY+19.78%
7.17 BJPY+20.37%
5.95 BJPY+19.93%
4.96 BJPY+2.71%
4.83 BJPY+28.92%
3.75 BJPY+218.52%
1.18 BJPY-48.29%
2.28 BJPY+29.02%
1.76 BJPY+79.45%
983.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AFC-HD AMS Life Science Co Stock analysis

What does AFC-HD AMS Life Science Co do? AFC-HD AMS Life Science Co., Ltd. generates revenue through its Healthcare segment, which produces and sells health foods, cosmetics, and OEM services for other brands. The Pharmaceutical segment manufactures and sells ethical drugs, over-the-counter drugs, and generic medicines. The company also manages restaurants via a subsidiary, contributing to its diversified income streams. Customers include businesses seeking OEM partnerships and consumers purchasing health and pharmaceutical products. The firm's products are sold under its own brand and through OEM agreements, targeting both individual consumers and corporate clients. The Healthcare segment focuses on wellness products, while the Pharmaceutical segment caters to medical needs with prescription and non-prescription drugs. The restaurant management subsidiary provides additional revenue from food service operations. Revenue is derived from the sale of health foods, cosmetics, Chinese medicine medicines, general medicines, and healthcare products within the Healthcare segment. The Pharmaceutical segment's income comes from ethical drugs, over-the-counter drugs, and generic medicines. The restaurant subsidiary's operations further support the company's financial structure through food service sales. AFC-HD AMS Life Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AFC-HD AMS Life Science Co stock

Current Liabilities of AFC-HD AMS Life Science Co is 24.15 B JPY in 2026.

Current Liabilities of AFC-HD AMS Life Science Co changed from 33.75 B JPY to 24.15 B JPY, representing a -28.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities AFC-HD AMS Life Science Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's AFC-HD AMS Life Science Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AFC-HD AMS Life Science Co

All Key Metrics — AFC-HD AMS Life Science Co